Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 26 | 2023 | 306 | 5.610 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2023 | 23 | 2.670 |
Why?
|
| Ischemic Attack, Transient | 13 | 2022 | 28 | 2.470 |
Why?
|
| Carotid Stenosis | 4 | 2022 | 8 | 1.660 |
Why?
|
| Fibrinolytic Agents | 7 | 2023 | 44 | 1.530 |
Why?
|
| Hypertension | 5 | 2023 | 489 | 1.470 |
Why?
|
| Brain Ischemia | 8 | 2023 | 37 | 1.370 |
Why?
|
| Telemedicine | 2 | 2020 | 187 | 1.050 |
Why?
|
| Thrombolytic Therapy | 4 | 2017 | 21 | 1.020 |
Why?
|
| Humans | 47 | 2024 | 18058 | 0.930 |
Why?
|
| Diabetes, Gestational | 6 | 2015 | 338 | 0.870 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 4 | 0.850 |
Why?
|
| Mentoring | 1 | 2022 | 28 | 0.820 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 6 | 0.750 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 6 | 0.750 |
Why?
|
| Female | 30 | 2024 | 12838 | 0.750 |
Why?
|
| Hospitals, Community | 1 | 2020 | 23 | 0.740 |
Why?
|
| Middle Aged | 21 | 2022 | 8073 | 0.710 |
Why?
|
| Breast Feeding | 3 | 2015 | 134 | 0.710 |
Why?
|
| Hospital Mortality | 1 | 2020 | 150 | 0.690 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.690 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.690 |
Why?
|
| Aged, 80 and over | 10 | 2022 | 1956 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 205 | 0.660 |
Why?
|
| Aged | 17 | 2022 | 6258 | 0.660 |
Why?
|
| Male | 20 | 2022 | 10173 | 0.630 |
Why?
|
| Pandemics | 1 | 2020 | 293 | 0.620 |
Why?
|
| Cerebral Angiography | 3 | 2011 | 6 | 0.570 |
Why?
|
| Lactation | 4 | 2014 | 50 | 0.530 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 613 | 0.530 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 170 | 0.510 |
Why?
|
| Hospitalization | 3 | 2021 | 813 | 0.500 |
Why?
|
| Thrombectomy | 2 | 2011 | 2 | 0.490 |
Why?
|
| Endarterectomy, Carotid | 3 | 2022 | 7 | 0.490 |
Why?
|
| Prospective Studies | 8 | 2024 | 1294 | 0.470 |
Why?
|
| Risk Factors | 12 | 2023 | 3394 | 0.460 |
Why?
|
| California | 8 | 2021 | 2327 | 0.430 |
Why?
|
| Pregnancy | 9 | 2023 | 1484 | 0.430 |
Why?
|
| Life Style | 4 | 2022 | 329 | 0.420 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 552 | 0.400 |
Why?
|
| Cohort Studies | 11 | 2020 | 2631 | 0.400 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 32 | 0.400 |
Why?
|
| Angioplasty | 1 | 2011 | 1 | 0.390 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 1023 | 0.380 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1259 | 0.370 |
Why?
|
| Adult | 12 | 2022 | 7696 | 0.350 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 251 | 0.350 |
Why?
|
| Early Diagnosis | 1 | 2009 | 40 | 0.340 |
Why?
|
| Incidence | 5 | 2022 | 1297 | 0.340 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 165 | 0.330 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 1 | 0.320 |
Why?
|
| Lipids | 2 | 2014 | 77 | 0.320 |
Why?
|
| Heart Failure | 2 | 2024 | 391 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2015 | 742 | 0.300 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 397 | 0.290 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 559 | 0.290 |
Why?
|
| Metabolic Syndrome | 2 | 2014 | 80 | 0.280 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 24 | 0.270 |
Why?
|
| Retrospective Studies | 5 | 2023 | 2498 | 0.270 |
Why?
|
| Asymptomatic Diseases | 2 | 2022 | 29 | 0.270 |
Why?
|
| Emergency Treatment | 1 | 2005 | 8 | 0.260 |
Why?
|
| Patient Discharge | 2 | 2020 | 150 | 0.250 |
Why?
|
| Asian Americans | 1 | 2005 | 184 | 0.250 |
Why?
|
| Blood Pressure | 2 | 2023 | 280 | 0.240 |
Why?
|
| Angioedema | 1 | 2023 | 8 | 0.240 |
Why?
|
| Physicians, Family | 1 | 2003 | 48 | 0.230 |
Why?
|
| Ticlopidine | 1 | 2013 | 16 | 0.230 |
Why?
|
| Carotid Artery, Internal | 1 | 2003 | 1 | 0.230 |
Why?
|
| Sex Factors | 3 | 2011 | 634 | 0.220 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 38 | 0.220 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 41 | 0.220 |
Why?
|
| Insulin Resistance | 2 | 2014 | 129 | 0.220 |
Why?
|
| Cancer Survivors | 1 | 2024 | 88 | 0.220 |
Why?
|
| United States | 10 | 2020 | 4119 | 0.200 |
Why?
|
| Adipose Tissue | 2 | 2015 | 59 | 0.200 |
Why?
|
| Glucose Intolerance | 1 | 2011 | 45 | 0.200 |
Why?
|
| Blood Pressure Determination | 2 | 2023 | 56 | 0.200 |
Why?
|
| Markov Chains | 3 | 2011 | 26 | 0.190 |
Why?
|
| Culturally Competent Care | 1 | 2020 | 12 | 0.190 |
Why?
|
| Ambulances | 1 | 2020 | 2 | 0.190 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 6 | 0.190 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 8 | 0.190 |
Why?
|
| Angiography | 1 | 2020 | 11 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2020 | 1137 | 0.190 |
Why?
|
| Racism | 1 | 2020 | 20 | 0.180 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.180 |
Why?
|
| Length of Stay | 1 | 2020 | 182 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2011 | 264 | 0.170 |
Why?
|
| Pregnancy in Adolescence | 1 | 2009 | 9 | 0.170 |
Why?
|
| Acute Disease | 2 | 2011 | 138 | 0.170 |
Why?
|
| Body Height | 1 | 2009 | 59 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2020 | 154 | 0.170 |
Why?
|
| Decision Trees | 2 | 2011 | 20 | 0.170 |
Why?
|
| Prognosis | 3 | 2016 | 619 | 0.160 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 164 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 454 | 0.160 |
Why?
|
| Registries | 3 | 2011 | 486 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 205 | 0.160 |
Why?
|
| Comorbidity | 1 | 2020 | 618 | 0.160 |
Why?
|
| Time Factors | 3 | 2017 | 1114 | 0.150 |
Why?
|
| Adolescent | 6 | 2016 | 3714 | 0.140 |
Why?
|
| Young Adult | 6 | 2016 | 2479 | 0.140 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 705 | 0.140 |
Why?
|
| Infant | 4 | 2016 | 1212 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 667 | 0.140 |
Why?
|
| Parity | 3 | 2011 | 75 | 0.140 |
Why?
|
| Age Factors | 2 | 2011 | 945 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 526 | 0.130 |
Why?
|
| Infant Formula | 1 | 2015 | 11 | 0.130 |
Why?
|
| Secondary Prevention | 3 | 2020 | 51 | 0.130 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2016 | 248 | 0.130 |
Why?
|
| Child Development | 1 | 2015 | 49 | 0.130 |
Why?
|
| Obesity | 2 | 2015 | 839 | 0.130 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 14 | 0.130 |
Why?
|
| Prevalence | 2 | 2011 | 892 | 0.120 |
Why?
|
| Adiponectin | 1 | 2014 | 22 | 0.120 |
Why?
|
| Leptin | 1 | 2014 | 30 | 0.120 |
Why?
|
| Child | 4 | 2016 | 2519 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2007 | 324 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2020 | 346 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 50 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 318 | 0.110 |
Why?
|
| Infant, Newborn | 3 | 2015 | 852 | 0.110 |
Why?
|
| Intracranial Thrombosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2005 | 357 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 595 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 29 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2012 | 71 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 9 | 0.100 |
Why?
|
| Inpatients | 1 | 2012 | 79 | 0.100 |
Why?
|
| Models, Econometric | 1 | 2011 | 11 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 70 | 0.100 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 375 | 0.090 |
Why?
|
| Gravidity | 2 | 2011 | 8 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 125 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 195 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 745 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 123 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 177 | 0.090 |
Why?
|
| Insulin | 2 | 2011 | 208 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 393 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 118 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2011 | 344 | 0.080 |
Why?
|
| Aspirin | 2 | 2013 | 67 | 0.080 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2008 | 3 | 0.080 |
Why?
|
| Reference Standards | 1 | 2008 | 17 | 0.080 |
Why?
|
| Ethnic Groups | 1 | 2011 | 504 | 0.080 |
Why?
|
| Anthropometry | 2 | 2015 | 63 | 0.080 |
Why?
|
| Waist Circumference | 2 | 2015 | 37 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2016 | 1428 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 1255 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 186 | 0.070 |
Why?
|
| China | 3 | 2011 | 126 | 0.070 |
Why?
|
| Research Design | 2 | 2015 | 393 | 0.070 |
Why?
|
| Body Weight | 2 | 2015 | 216 | 0.070 |
Why?
|
| Pacific Islands | 1 | 2005 | 5 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2010 | 1309 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 42 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2005 | 30 | 0.070 |
Why?
|
| Cultural Diversity | 1 | 2005 | 17 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2005 | 249 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 225 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2005 | 184 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 1346 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 31 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 16 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 57 | 0.060 |
Why?
|
| Catheterization, Peripheral | 1 | 2003 | 3 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2013 | 160 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2013 | 63 | 0.060 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 34 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2003 | 109 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2023 | 60 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 65 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2022 | 17 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 16 | 0.050 |
Why?
|
| Mass Screening | 1 | 2008 | 678 | 0.050 |
Why?
|
| Infant Food | 1 | 2011 | 8 | 0.050 |
Why?
|
| Bottle Feeding | 1 | 2011 | 8 | 0.050 |
Why?
|
| Contraception | 1 | 2011 | 25 | 0.050 |
Why?
|
| Diet | 1 | 2024 | 359 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 106 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 46 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 350 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2020 | 12 | 0.050 |
Why?
|
| Prejudice | 1 | 2020 | 24 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 13 | 0.050 |
Why?
|
| Self-Management | 1 | 2020 | 26 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2020 | 77 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 40 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 114 | 0.040 |
Why?
|
| Risk | 2 | 2011 | 552 | 0.040 |
Why?
|
| Health Education | 1 | 2020 | 118 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 81 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2009 | 162 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 193 | 0.040 |
Why?
|
| Educational Status | 1 | 2009 | 205 | 0.040 |
Why?
|
| Probability | 1 | 2009 | 86 | 0.040 |
Why?
|
| Body Composition | 1 | 2009 | 80 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2009 | 182 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 240 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 431 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 316 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2009 | 317 | 0.040 |
Why?
|
| African Americans | 1 | 2020 | 485 | 0.040 |
Why?
|
| Goals | 1 | 2016 | 29 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2016 | 78 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 478 | 0.030 |
Why?
|
| Skinfold Thickness | 1 | 2015 | 18 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2009 | 961 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2014 | 12 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2014 | 14 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2014 | 93 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 255 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 306 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 272 | 0.030 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 2 | 0.030 |
Why?
|
| Heparin | 1 | 2012 | 9 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 36 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 129 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 147 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 16 | 0.020 |
Why?
|
| Centers for Medicare and Medicaid Services (U.S.) | 1 | 2011 | 7 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 10 | 0.020 |
Why?
|
| Contraindications | 1 | 2011 | 16 | 0.020 |
Why?
|
| Neoplasms | 1 | 2016 | 464 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 28 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 2 | 0.020 |
Why?
|
| National Health Programs | 1 | 2010 | 10 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 45 | 0.020 |
Why?
|
| Medicare | 1 | 2011 | 206 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 79 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 252 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 157 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2010 | 221 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2010 | 303 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 465 | 0.020 |
Why?
|
| United Kingdom | 1 | 2007 | 30 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2006 | 9 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2006 | 13 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2011 | 734 | 0.020 |
Why?
|
| Logistic Models | 1 | 2007 | 953 | 0.020 |
Why?
|
Concepts
(242)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(18)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->